Proposed therapies in primary biliary cholangitis

Annarosa Floreani, Ying Sun, Zheng Sheng Zou, Baosen Li, Nora Cazzagon, Christopher Bowlus, M. Eric Gershwin

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


Primary biliary cholangitis (PBC), previously known as primary biliary cirrhosis, is a model autoimmune disease with chronic cholestasis characterized by the hallmark of anti-mitochondrial antibodies and treated with ursodeoxycholic acid (UDCA). However, approximately 20-40% of patients incompletely respond to UDCA and have an increased risk of disease progression. Although there have been significant advances in the immunobiology of PBC, these have yet to be translated into newer therapeutic modalities. Current approaches to controlling the immune response include broad immunosuppression with corticosteroids as well as targeted therapies directed against T and B cells. In contrast, ameliorating cholestasis is the focus of other therapies in development, including obeticholic acid. In this article the authors will discuss ongoing clinical trials and, in particular, the rationale for choosing agents that may effectively target the aberrant immune response.

Original languageEnglish (US)
Pages (from-to)371-382
Number of pages12
JournalExpert Review of Gastroenterology and Hepatology
Issue number3
StatePublished - Mar 3 2016


  • biologic agents
  • budesonide
  • fatigue
  • fibrates
  • obeticholic acid
  • Primary biliary cirrhosis
  • pruritus
  • treatment
  • UDCA

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology


Dive into the research topics of 'Proposed therapies in primary biliary cholangitis'. Together they form a unique fingerprint.

Cite this